Suppr超能文献

网络药理学、分子对接分析和分子动力学模拟在治疗肝纤维化中的应用。

Network Pharmacology, Molecular Docking Analysis and Molecular Dynamics Simulation of in the Treatment of Liver Fibrosis.

机构信息

Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.

Nanjing Foreign Language School, Nanjing, China.

出版信息

Curr Pharm Des. 2024;30(17):1326-1340. doi: 10.2174/0113816128297074240327090020.

Abstract

BACKGROUND

Traditional Chinese medicine (SB), one of the clinical firstline heat-clearing drugs, has obvious symptomatic advantages for hepatic fibrosis with dampness-heat stasis as its syndrome. We aim to predict and validate the potential mechanism of active ingredients against liver fibrosis more scientifically and effectively.

METHODS

The underlying mechanism of in inhibiting hepatic fibrosis was studied by applying network pharmacology, molecular docking and molecular dynamics simulation. Expression levels of markers in activated Hepatic Stellate Cells (HSC) after administration of three extracts were determined by Western blot and Real-time PCR, respectively, in order to verify the anti-fibrosis effect of the active ingredients Results: There are 164 common targets of drugs and diseases screened and 115 signaling pathways obtained, which were mainly associated with protein phosphorylation, senescence and negative regulation of the apoptotic process. Western blot and Real-time PCR showed that extracts could reduce the expression of HSC activation markers, and Oroxylin A had the strongest inhibitory effect on it. Molecular docking results showed that Oroxylin A had high binding activity to target proteins. Molecular dynamics simulation demonstrates promising stability of the Oroxylin A-AKT1 complex over the simulated MD time of 200 ns.

CONCLUSION

active ingredients may inhibit HSC proliferation, reduce the generation of pro-inflammatory factors and block the anti-inflammatory effect of inflammatory signal transduction by inducing HSC apoptosis and senescence, thus achieving the effect of anti-fibrosis.

摘要

背景

中药(SB)是湿热证肝纤维化的一线临床清热药物之一,具有明显的症状优势。我们旨在更科学有效地预测和验证针对肝纤维化的活性成分的潜在机制。

方法

应用网络药理学、分子对接和分子动力学模拟研究了对肝纤维化的抑制作用的潜在机制。通过 Western blot 和实时 PCR 分别测定三种提取物给药后活化的肝星状细胞(HSC)中标志物的表达水平,以验证活性成分的抗纤维化作用。

结果

筛选出 164 个药物和疾病的共同靶点,获得 115 个信号通路,主要与蛋白磷酸化、衰老和细胞凋亡过程的负调控有关。Western blot 和实时 PCR 显示,提取物可降低 HSC 活化标志物的表达,其中白杨素 A 的抑制作用最强。分子对接结果表明白杨素 A 对靶蛋白具有高结合活性。分子动力学模拟表明,在模拟的 200nsMD 时间内,白杨素 A-AKT1 复合物具有良好的稳定性。

结论

活性成分可能通过诱导 HSC 凋亡和衰老,抑制 HSC 增殖、减少促炎因子的产生并阻断炎症信号转导的抗炎作用,从而达到抗纤维化的效果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验